Urinary excretion profiles of two major triazolam metabolites, α-hydroxytriazolam and 4-hydroxytriazolam

Journal of Analytical Toxicology

Volumn 29, Issue 4, 2005, Pages 240-243

  Tsujikawa, Kenji ^a   Kuwayama, Kenji ^a   Miyaguchi, Hajime ^a   Kanamori, Tatsuyuki ^a   Iwata, Yuko ^a   Inoue, Hiroyuki ^a   Kishi, Tohru ^a  

^a NATIONAL RESEARCH INSTITUTE OF POLICE SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTRIAZOLAM; ALPHA HYDROXYTRIAZOLAM; DRUG METABOLITE; NITRAZEPAM; TRIAZOLAM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG URINE LEVEL; EXTRACTION; HUMAN; HUMAN EXPERIMENT; HYDROLYSIS; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; SINGLE DRUG DOSE; URINARY EXCRETION;

EID: 20444477906     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/29.4.240     Document Type: Article

References (13)

1. T. Kronbach, D. Mathys, M. Umeno, F.J. Gonzalez, and U.A. Meyer. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36: 89-96 (1989).
2. F.S. Eberts, Y. Philopoulos, L.M. Reineke, and R.W. Vliek. Triazolam disposition. Clin. Pharmacol. Ther. 29: 81-93 (1981).
3. B. Marc, F. Baudry, P. Vaquero, L. Zerrouki, S. Hassnaoui, and H. Douceron. Sexual assault under benzodiazepine submission in a Paris suburb. Arch. Gynecol. Obstet. 263: 193-197 (2000).
4. M.A. ElSohly, S. Feng, S.J. Salamone, and R. Wu. A sensitive GC-MS procedure for the analysis of flunitrazepam and its metabolites in urine. J. Anal. Toxicol. 21: 335-340 (1997).
5. A. Smith-Kielland, B. Skuterud, K.M. Olsen, and J. Morland. Urinary excretion of diazepam metabolites in healthy volunteers and drug users. Scand. J. Clin. Lab. Invest. 61: 237-246 (2001).
6. W. Fishman, B. Springer, and B. Brunetti. Application of an improved glucuronidase assay method to the study of human blood β-glucuronidase. J. Biol. Chem. 173: 449-456 (1948).
7. K. Tsujikawa, K. Kuwayama, T. Kanamori, Y. Iwata, Y. Ohmae, H. Inoue, and T. Kishi. Optimized conditions for the enzymatic hydrolysis of α-hydroxytriazolam-glucuronide in human urine. J. Health Sci. 50: 286-289 (2004).
8. O. Beck, P. Lafolie, P. Hjemdahl, S. Borg, G. Odelius, and P. Wirbing. Detection of benzodiazepine intake in therapeutic doses by immunoanalysis of urine: two techniques evaluated and modified for improved performance. Clin. Chem. 38: 271-275 (1992).
9. A.D. Fraser and R. Meatherall. Comparative evaluation of five immunoassays for the analysis of alprazolam and triazolam metabolites in urine: effects of lowering the screening and GC-MS cut-off values. J. Anal. Toxicol. 20: 217-223 (1996).
10. A.D. Fraser and R. Meatherall. Improved cross-reactivity to alpha OH triazolam in the BMC CEDIA DAU urine benzodiazepine assay. Ther. Drug Monit. 20: 331-334 (1998).
11. T. Tateishi, M. Watanabe, H. Nakura, M. Asoh, H. Shirai, Y. Mizorogi, S. Kobayashi, K.E. Thummel, and G.R. Wilkinson. CYP3A activity in European American and Japanese men using midazolam as an in vitro probe. Clin. Pharmacol. Ther. 69: 333-339 (2001).
12. J.C. Gorski, D.R. Jones, B.D. Haehner-Daniels, M.A. Hamman, E.M. O'Mara, and S.D. Hall. The contribution of intestinal and hepatic CYP3A4 to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther. 64: 133-143 (1998).
13. D.J. Greenblatt, J.S. Harmatz, L.L.V. Moltke, C.E. Wright, A.L.B. Durol, L.M. Harrel-Joseph, and R.I. Shader. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J. Pharmacol. Exp. Ther. 293: 435-443 (2000).